Australia's most trusted
source of pharma news
Wednesday, 15 January 2025
Posted 12 September 2024 PM
A needle-free bird flu vaccine is set to enter clinical trials in Australia with $43 million in backing from the US Government.
The Phase 1 clinical trial will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine, sourced from the US National stockpile, when dosed intradermally with Vaxxas' high-density microarray patch (HD-MAP) as well as through conventional needle and syringe.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.